文献速递免疫规划传染病防控与疫情报告

基于SARS-CoV-2刺突序列的距离作为COVID-19疫苗结合抗体应答的标志物

SARS-CoV-2 spike sequence-based distance as a marker of binding antibody response to COVID-19 vaccines.
PubMed 文献 · Vaccine · 2025-09-29

研究纳入728名未感染过SARS-CoV-2并接种祖先株mRNA或载体疫苗后以同源或异源方式加强(含二价B.1.351 mRNA疫苗)的个体,评估疫苗与检测用刺突抗原的蛋白质组距离对疫苗诱导抗体应答的预测能力。基础免疫后抗体应答随刺突抗原不同而异,疫苗与检测抗原每差10个氨基酸平均低36%(95%CI:30%至43%);加强后应答变异较小且与刺突距离弱相关(每10个氨基酸低17%,95%CI:14%至20%)。

要点

  • 基础免疫后,疫苗与检测刺突抗原每差10个氨基酸,抗体应答平均低36%(95%CI:30%至43%)。
  • 加强后抗体应答跨抗原变异较小,与刺突距离弱相关(每10个氨基酸低17%,95%CI:14%至20%)。
  • 给定抗原的几何平均抗体应答几乎可由其与疫苗的序列距离完美预测。

核心结论

  • 基础免疫后疫苗诱导的结合抗体应答可由检测抗原与疫苗刺突序列的基于序列的距离近乎完美预测。
  • 加强后抗体应答跨抗原变异较小且与刺突距离仅弱相关。
  • 鉴于人群已经历多轮疫苗接种和感染,可能需从代表性人群测量疫苗诱导抗体应答以预测COVID-19疫苗对未来毒株的效力。

研究设计与样本

  • 研究纳入728名无既往SARS-CoV-2感染史的个体,接种祖先病毒为基础的mRNA和载体COVID-19疫苗进行基础免疫,并以同源或异源方式用mRNA、载体或蛋白为基础的COVID-19疫苗(包括二价B.1.351 mRNA疫苗)加强。
  • 采用基础免疫后和加强后结合抗体应答,评估对2020年至2021年间出现的22种SARS-CoV-2刺突抗原应答的变异程度和驱动因素。
  • 评估疫苗与检测刺突抗原之间的蛋白质组距离对疫苗诱导抗体应答的预测能力。

主要发现

  • 基础免疫后,抗体应答随刺突抗原不同而异,疫苗与检测刺突抗原每差10个氨基酸平均低36%(95%CI:30%至43%)。
  • 给定抗原的几何平均抗体应答几乎可由该抗原与疫苗的基于序列的距离完美预测。
  • 加强后应答跨抗原变异较小,与刺突距离弱相关(每10个氨基酸低17%;95%CI:14%至20%)。
  • 结合抗体在个体间的高变异仅部分由参与者特征解释。

局限性

  • 结合抗体在个体间的高变异仅部分由参与者特征解释。
  • 鉴于人群已经历多轮疫苗接种和感染,可能需从代表性人群测量疫苗诱导抗体应答以预测COVID-19疫苗对未来毒株的效力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

COVID-19 vaccines based on ancestral SARS-CoV-2 have proven highly effective at reducing the risk of illness, especially severe disease. Both binding and neutralizing antibodies have been demonstrated to be strong predictors of the level of vaccine efficacy (VE). Both VE and vaccine-induced antibody responses have been shown to be lower against emergent SARS-CoV-2 viruses; therefore, predicting COVID-19 VE against emergent viruses is critical for decision-making regarding the composition of new vaccines. The data needed to enable such prediction are unclear. We report on 728 individuals without prior SARS-CoV-2 infection who received primary vaccination with ancestral-virus-based mRNA and vector-based COVID-19 vaccines and who were boosted in a homologous or heterologous fashion with mRNA, vector, or protein-based COVID-19 vaccines including a bivalent B.1.351 mRNA vaccine. Post-prime and post-boost binding antibody responses were used to evaluate the extent and drivers of variability in these responses to 22 SARS-CoV-2 Spike antigens from viruses that emerged between 2020 and 2021. We evaluated how well proteomic distance between the vaccine and assay Spike antigen predicted the vaccine-induced antibody response. Following primary vaccination, antibody responses varied across Spike antigens and were, on average, 36 % lower per 10-amino acid (AA) difference between the vaccine and assay Spike antigen (95 % CI: 30 % to 43 %). The geometric mean antibody response to a given antigen was nearly perfectly predicted by the sequence-based distance of the antigen to the vaccine. Post-boost responses were less variable across antigens and weakly associated with Spike distance (17 % lower per 10-AA difference; 95 % CI: 14 % to 20 %). The high variability in binding antibodies across individuals was only partially explained by participant characteristics. Given that populations now have experienced multiple rounds of prior vaccination and infection, measurement of vaccine-induced antibody responses from representative populations will likely be needed to predict the efficacy of COVID-19 vaccines against future strains.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Dominguez Islas CP, Magaret CA, Molitor C, et al. SARS-CoV-2 spike sequence-based distance as a marker of binding antibody response to COVID-19 vaccines. Vaccine. 2025. PMID: 41027157. doi:10.1016/j.vaccine.2025.127738

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。